Medical cannabis collection · Sources reviewed 11 October 2026
A treatment can make an illness more bearable without treating the illness itself. That distinction is especially important in cancer care, where relief of nausea, pain or distress can be valuable but should not be presented as evidence that a tumour is shrinking or survival is improving.
On this page
“Whether cannabis and/or cannabinoids can improve other supportive care outcomes remains uncertain.”
ASCO guideline, 2024“Other” follows the guideline’s discussion of refractory chemotherapy-related nausea and vomiting. This is a statement about uncertainty, not a dismissal of patients’ symptoms.
What the cancer guideline says
ASCO recommends against using cannabis or cannabinoids as a cancer-directed treatment outside a clinical trial. It identifies a possible role in persistent chemotherapy-related nausea and vomiting when added to conventional antiemetics. Those two statements belong together: a supportive use does not establish an anti-cancer use.
Laboratory findings can explain why a treatment deserves investigation. They cannot show that a preparation safely reaches an effective concentration in a person or improves survival. Replacing established cancer treatment on the basis of cell-culture findings makes a much larger claim than those experiments support.
Pain needs its own evidence
The chronic-pain literature should not be treated as a single verdict on cancer pain. Study populations, background medicines and goals differ. A 2025 systematic review of cannabinoids for palliation of cancer-associated symptoms brings together this condition-specific literature; it included both trials and observational studies, and found reductions in pain and anxiety compared with baseline. Before-and-after improvement does not by itself establish superiority to placebo. The authors also identified substantial concerns about bias and adverse effects, especially with THC-predominant products. Cancer-symptom systematic review, 2025.
An individual’s wish for better comfort deserves attention even when the average research effect is uncertain. A review can identify the intended benefit, previous approaches and whether a carefully supervised option is justified. It should not promise opioid reduction or advise a person to reduce analgesia without the treating team.
Appetite is not the same as reversing cachexia
Feeling hungry, eating more, maintaining weight and retaining muscle are different outcomes. Cancer-associated cachexia is more complex than a lack of appetite. A review of ten studies, including four randomised trials, found no convincing benefit for appetite, weight gain or quality of life. Much of the evidence was of low quality, and positive patient reports in observational studies did not resolve the uncertainty in controlled comparisons. Cachexia systematic review, 2022.
A report that someone enjoyed a meal is meaningful as an experience. It cannot alone establish reversal of wasting or a change in prognosis. Nutritional support, symptom assessment and the wider oncology plan remain relevant.
Treatment burden is part of the result
Sleepiness may be welcome at one time and distressing at another. A person may prioritise conversation, mobility or alertness with family. Dizziness, cognitive effects, additional administration tasks and the cost of treatment can therefore matter as much as a numerical symptom score.
A 2024 palliative-care review discusses cannabinoids in this broader clinical setting. It is a narrative discussion, rather than a definitive trial of every possible use. Palliative-care review, 2024. The practical question remains whether the proposed intervention serves this person’s goals with an acceptable burden.
A better conversation with the team
People should be able to disclose prescribed, non-prescribed and contemplated cannabis use without fearing that the conversation will become a moral judgement. An accurate account lets the team consider interactions and avoid fragmented care. Compassion and careful evidence are complementary: neither requires exaggerating what a cannabinoid has been shown to do.
References and further reading
- Braun et al. (2024). ASCO guideline on cannabis and cannabinoids in adults with cancer.
- Indications of Cannabinoids for the Palliation of Cancer-Associated Symptoms: systematic review and meta-analysis (2025).
- Cannabinoid interventions for improving cachexia outcomes in cancer: systematic review and meta-analysis (2022).
- Medicinal cannabis – has it found a place in palliative care? Narrative review (2024).
Educational information, not an individual prescribing plan. Decisions about medicines belong with the treating clinician. External reference links open in a new tab.